Cite

HARVARD Citation

    Isakoff, S. et al. (n.d.). A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors. European journal of cancer. pp. S137-S138. [Online]. 
  
Back to record